Project Echo: Tele-mentoring to manage immune-related adverse events in patients receiving cancer immunotherapies - September 20, 2022
This page is for learners who attended the September 20, 2022, virtual session to claim credit.
Claiming Credit
Target Audience
The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.
Learning Objectives
- Apply evidence-based practices for the monitoring and management of irAEs in patients receiving cancer immunotherapies
- Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAEs in patients receiving cancer immunotherapies
- Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies
Additional Information
Attachment | Size |
---|---|
![]() | 108.11 KB |
Available Credit
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCBoston University Chobanian & Avedisian School of Medicine, Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
- 1.00 ParticipationBoston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.